| Results of Operations and Financial Condition. On November 5, 2026, Iovance Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2026, and an update on recent developments. A copy of that press release is furnished as Exhibit 99.1. The information furnished under this Item 2.02, including the accompanying Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange…

Results of Operations and Financial Condition. On August 6, 2026, Iovance Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2026, and an update on recent developments. A copy of that press release is furnished as Exhibit 99.1. The information furnished under this Item 2.02, including the accompanying Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of…

Results of Operations and Financial Condition. On May 7, 2026, Iovance Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2026, and an update on recent developments. A copy of that press release is furnished as Exhibit 99.1. The information furnished under this Item 2.02, including the accompanying Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 193…

Director — Wendy Yarno: Ms. Yarno is retiring from the Board and will not stand for re-election at the Annual Meeting.

Results of Operations and Financial Condition. On February 24, 2026, Iovance Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2025, and an update on recent developments. A copy of that press release is furnished as Exhibit 99.1. The information furnished under this Item 2.02, including the accompanying Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Secu…

Results of Operations and Financial Condition. On November 6, 2025, Iovance Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025, and an update on recent developments. A copy of that press release is furnished as Exhibit 99.1. The information furnished under this Item 2.02, including the accompanying Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of…

Entry Into a Material Definitive Agreement. On August 22, 2025, Iovance Biotherapeutics, Inc. (the “ Company ”) entered into an Amended and Restated Open Market Sale Agreement (the “ Agreement ”) with Jefferies LLC (“ Jefferies ”) with respect to an at the market offering program, under which the Company may, from time to time in its sole discretion, issue and sell through Jefferies, acting as sales agent, up to $350.0 million of shares of the Company's common stock, par value $0.000041666 pe…

Chief Financial Officer — Corleen Roche: Corleen Roche was appointed as the new Chief Financial Officer.

Results of Operations and Financial Condition. On August 7, 2025, Iovance Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025, and an update on recent developments. A copy of that press release is furnished as Exhibit 99.1. The information furnished under this Item 2.02, including the accompanying Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, a…

Chief Financial Officer — Corleen Roche: Ms. Corleen Roche was hired as the new Chief Financial Officer from an external position.

Chief Financial Officer and Principal Financial Officer and Principal Accounting Officer — Jean-Marc Bellemin: Jean-Marc Bellemin resigned to pursue other opportunities.

Chief Financial Officer — Jean-Marc Bellemin: The CFO is resigning to pursue other opportunities.

Results of Operations and Financial Condition. On May 8, 2025, Iovance Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2025, and an update on recent developments. A copy of that press release is furnished as Exhibit 99.1. The information furnished under this Item 2.02, including the accompanying Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as…

Results of Operations and Financial Condition. On February 27, 2025, Iovance Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2024 and an update on recent developments. A copy of that press release is furnished as Exhibit 99.1. The information furnished under this Item 2.02, including the accompanying Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Secur…

Entry into a Material Definitive Agreement. As a result of an increase in remote employees, including in the local Bay Area, and continued efforts to identify cost reduction opportunities, Iovance Biotherapeutics, Inc. (the “Company”) will relocate its offices within the same building of its current San Carlos, California headquarters. As such, on November 15, 2024, the Company entered into a sublease agreement (the “New Headquarters Lease”) with Vaxcyte, Inc. for Suite 100 of 825 Industrial…

Termination of a Material Definitive Agreement. On November 15, 2024, the Company entered into an Agreement for Termination of Lease and Voluntary Surrender of Premises with the Landlord (the “Termination Agreement”), in connection with the termination of that certain Lease Agreement, dated as of February 8, 2021, with the Landlord (the “Prior Headquarters Lease”) of Suite 400 of the Building (the “Prior Premises”). The Prior Premises consists of 49,918 rentable square feet. Pursuant to the T…

Results of Operations and Financial Condition. On November 7, 2024, Iovance Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2024 and an update on recent developments. A copy of that press release is furnished as Exhibit 99.1. The information furnished under this Item 2.02, including the accompanying Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1…

Results of Operations and Financial Condition. On August 8, 2024, Iovance Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2024 and an update on recent developments. A copy of that press release is furnished as Exhibit 99.1. The information furnished under this Item 2.02, including the accompanying Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as…

Results of Operations and Financial Condition. On May 9, 2024, Iovance Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2024 and an update on recent developments. A copy of that press release is furnished as Exhibit 99.1. The information furnished under this Item 2.02, including the accompanying Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934…

Director — General (Ret.) Merrill A. McPeak: General McPeak is retiring and not standing for re-election, with Dr. Frederick G. Vogt nominated to fill the vacancy.

Results of Operations and Financial Condition. On February 28, 2024, Iovance Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023 and an update on recent developments. A copy of that press release is furnished as Exhibit 99.1. The information furnished under this Item 2.02, including the accompanying Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Secur…

Results of Operations and Financial Condition. Iovance Biotherapeutics, Inc. (the “Company”) reports that as of December 31, 2023, the Company had approximately $346.3 million in cash, cash equivalents, investments, and restricted cash ($114.9 million of cash and cash equivalents, $165.0 million in short-term investments, and $66.4 million in restricted cash). The foregoing information reflects the Company's preliminary estimates with respect to cash, cash equivalents, investments, and restri…

Entry into a Material Definitive Agreement On February 20, 2024, Iovance Biotherapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Barclays Capital Inc. and Goldman Sachs & Co. LLC (collectively, the “Underwriters”), pursuant to which the Company agreed to issue and sell up to 23,014,000 shares of common stock (the “Shares”) (the “Offering”). The Shares were offered and sold in the Offering at the offering price of $9.15 pe…

Results of Operations and Financial Condition. On November 7, 2023, Iovance Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023 and an update on recent developments. A copy of that press release is furnished as Exhibit 99.1. The information furnished under this Item 2.02, including the accompanying Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1…

Results of Operations and Financial Condition. On August 8, 2023, Iovance Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023 and an update on recent developments. A copy of that press release is furnished as Exhibit 99.1. The information furnished under this Item 2.02, including the accompanying Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (th…